Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Aktis Oncology, Inc.

AKTS · Nasdaq · CIK 0002035832 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

17 Form 4 transaction lines observed in the same window
11 sales · 6 option, withholding, award, gift or other lines

Last qualifying purchase2026-01-12 · Foley Todd · $4.2M

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Czibere AkosChief Medical Officer
○▼○▼
Herrmann KenDirector
○▼○▼
Ron-Bigger ShulamitChief Operating Officer
○▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-01-12 · Foley Todd.

Recent Form 4 activity

9Purchases
11Sales
23Other Form 4 lines
12SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING11 sale line(s) · context only
OTHER6 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-31.5%
3M
-30.5%
6M
+6.2%
12M
—

Volatility & liquidity

Volatility
68.4%
Beta
—
Avg daily value
—

Valuation

Market cap
—
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-02 · Price source: OpenBB/yfinance · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,715,294
Previous report
3,252,475
Avg daily volume
645,721
Days to cover
7.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-01-12GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P.Purchase (P)Common Stock1,112,777USD 18.00USD 20,029,986SEC filing ↗
2026-01-12Foley ToddPurchase (P)Common Stock232,870USD 18.00USD 4,191,660SEC filing ↗
2026-01-12EVNIN LUKE; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLCPurchase (P)Common Stock1,112,777USD 18.00USD 20,029,986SEC filing ↗
2026-01-12VIDA VENTURES II-A, LLC; Vida Ventures II, LLCPurchase (P)Common Stock835,000USD 18.00USD 15,030,000SEC filing ↗
2026-01-12Kim Helen SusanPurchase (P)Common Stock835,000USD 18.00USD 15,030,000SEC filing ↗
2026-01-12EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock2,222,222USD 18.00USD 39,999,996SEC filing ↗

Form 4 evidence

43 transaction lines in the latest 365-day window; 43 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-23Czibere AkosSale (S)Common Stock12,500USD 20.69USD 258,592SEC filing ↗
2026-09-23Czibere AkosOption exercise / conversion (M)Common Stock12,500USD 4.95USD 61,875SEC filing ↗
2026-07-20Herrmann KenSale (S)Common Stock4,856USD 24.56USD 119,263SEC filing ↗
Show recent Form 4 evidence (23 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-23Czibere AkosSale (S)Common Stock12,500USD 20.69USD 258,592SEC filing ↗
2026-09-23Czibere AkosOption exercise / conversion (M)Common Stock12,500USD 4.95USD 61,875SEC filing ↗
2026-07-20Herrmann KenSale (S)Common Stock4,856USD 24.56USD 119,263SEC filing ↗
2026-07-20Herrmann KenOption exercise / conversion (M)Common Stock4,856USD 0.59USD 2,859SEC filing ↗
2026-07-17Herrmann KenSale (S)Common Stock3,065USD 25.21USD 77,269SEC filing ↗
2026-07-17Herrmann KenOption exercise / conversion (M)Common Stock3,065USD 0.08USD 245SEC filing ↗
2026-07-08Ron-Bigger ShulamitSale (S)Common Stock50,000USD 27.75USD 1,387,604SEC filing ↗
2026-07-08Ron-Bigger ShulamitOption exercise / conversion (M)Common Stock50,000USD 3.66USD 183,000SEC filing ↗
2026-07-08Czibere AkosSale (S)Common Stock50,000USD 27.77USD 1,388,686SEC filing ↗
2026-07-08Czibere AkosOption exercise / conversion (M)Common Stock50,000USD 4.95USD 247,500SEC filing ↗
2026-01-12GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P.Purchase (P)Common Stock1,112,777USD 18.00USD 20,029,986SEC filing ↗
2026-01-12GADICKE ANSBERT; MPM ASSET MANAGEMENT LLC; Oncology Impact Private Investment Fund 2, L.P.C (C)Common Stock8,805,578USD —USD —SEC filing ↗
2026-01-12Foley ToddPurchase (P)Common Stock232,870USD 18.00USD 4,191,660SEC filing ↗
2026-01-12Foley ToddC (C)Common Stock4,002,533USD —USD —SEC filing ↗
2026-01-12EVNIN LUKE; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLCPurchase (P)Common Stock1,112,777USD 18.00USD 20,029,986SEC filing ↗
2026-01-12EVNIN LUKE; MPM ASSET MANAGEMENT INVESTORS BV2018 LLC; MPM BIOVENTURES 2018 (B), L.P.; MPM BIOVENTURES 2018, L.P.; MPM BioVentures 2018 GP LLC; MPM BioVentures 2018 LLC; MPM ONCOLOGY INNOVATIONS FUND LP; MPM Oncology Innovations Fund GP LLCC (C)Common Stock8,805,578USD —USD —SEC filing ↗
2026-01-12VIDA VENTURES II-A, LLC; Vida Ventures II, LLCPurchase (P)Common Stock835,000USD 18.00USD 15,030,000SEC filing ↗
2026-01-12VIDA VENTURES II-A, LLC; Vida Ventures II, LLCC (C)Common Stock4,994,212USD —USD —SEC filing ↗
2026-01-12Segal Lloyd MitchellC (C)Common Stock19,631USD —USD —SEC filing ↗
2026-01-12Kim Helen SusanPurchase (P)Common Stock835,000USD 18.00USD 15,030,000SEC filing ↗
2026-01-12Kim Helen SusanC (C)Common Stock4,994,212USD —USD —SEC filing ↗
2026-01-12EcoR1 Capital, LLC; NODELMAN OLEGPurchase (P)Common Stock2,222,222USD 18.00USD 39,999,996SEC filing ↗
2026-01-12EcoR1 Capital, LLC; NODELMAN OLEGC (C)Common Stock2,602,247USD —USD —SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerAKTS
CIK0002035832
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history43 transaction lines from 2026-01-12 to 2026-09-23
9 P purchase lines · 11 S sale lines · 23 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.